Literature DB >> 8930772

Use of beta-adrenergic receptor blockers in blacks.

L M Prisant1, G A Mensah.   

Abstract

Beta adrenergic receptor blockers (beta-blockers) are an important class of drugs in the management of patients with cardiovascular diseases. These drugs have been shown to reduce mortality in hypertension and prolong survival in patients with coronary heart disease. Although hypertension and coronary heart disease account for the majority of excess cardiovascular morbidity and mortality in blocks, beta-blockers continue to be underprescribed in this ethnic group. The magnitude of blood pressure reduction in black patients with hypertension has been consistently less during monotherapy with nonselective beta-blockers than with diuretics. However, the highly selective beta-blocker bisoprolol has been shown to be as effective as diuretics and is equally effective in black and nonblack patients with hypertension. In general, no racial differences in efficacy are noted when beta-blockers are used with diuretics as combination therapy for hypertension. Black patients should not be denied beta-blocker therapy because of an anticipated suboptimal response, especially when there are clear indications for treatment (e.g., for migraine, hyperthyroidism, arrhythmia control, and after myocardial infarction).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8930772     DOI: 10.1002/j.1552-4604.1996.tb04752.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  10 in total

Review 1.  Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment.

Authors:  Valentine J Burroughs; Randall W Maxey; Richard A Levy
Journal:  J Natl Med Assoc       Date:  2002-10       Impact factor: 1.798

Review 2.  Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats.

Authors:  Domenic A Sica
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Low-dose combination therapy as first-line hypertension treatment for blacks and nonblacks.

Authors:  L M Prisant; J M Neutel; K Ferdinand; V Papademetriou; V DeQuattro; W D Hall; M R Weir
Journal:  J Natl Med Assoc       Date:  1999-01       Impact factor: 1.798

4.  Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension.

Authors:  Ali Jawa; Senthil Nachimuthu; Merri Pendergrass; Sunil Asnani; Vivian Fonseca
Journal:  J Diabetes Complications       Date:  2008-04-16       Impact factor: 2.852

Review 5.  Hypertension-related morbidity and mortality in African Americans--why we need to do better.

Authors:  Keith C Ferdinand; Elijah Saunders
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-01       Impact factor: 3.738

6.  The Effect of Nebivolol on Office Blood Pressure of Blacks Residing in Sub-Saharan Africa (A Pilot Study).

Authors:  Dike Ojji; Boni Maxime Ale; Lamkur Shedul; Ejiroghene Umuerri; Emmanuel Ejim; Chizindu Alikor; Charles Agunyenwa; Uche Njideofor; Helen Eze; Victor Ansa
Journal:  Front Cardiovasc Med       Date:  2021-01-11

7.  Should beta blockers be used in the treatment of hypertension in the elderly?

Authors:  L Michael Prisant
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Jul-Aug       Impact factor: 3.738

8.  Influence of heart failure on the prognosis of patients with acute myocardial infarction in southwestern China.

Authors:  Fuxue Deng; Yong Xia; Michael Fu; Yunfeng Hu; Fang Jia; Yeffry Rahardjo; Yingyi Duan; Linjing He; Jing Chang
Journal:  Exp Ther Med       Date:  2016-03-31       Impact factor: 2.447

Review 9.  Meeting the challenge to improve the treatment of hypertension in blacks.

Authors:  Antonio Alberto Lopes; Sherman A James; Friedrich K Port; Akinlolu O Ojo; Lawrence Y Agodoa; Kenneth A Jamerson
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Nov-Dec       Impact factor: 3.738

10.  The efficacy and tolerability of nebivolol in hypertensive African American patients.

Authors:  Elijah Saunders; William B Smith; Karen B DeSalvo; Will A Sullivan
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-11       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.